FDA ad­comm will re­ex­am­ine ap­proval of check­point in­hibitors in two can­cers based on key bio­mark­er

The FDA’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee will meet Thurs­day to dis­cuss whether sev­er­al im­mune check­point in­hibitor drugs should come with nar­row­er in­di­ca­tions in two can­cers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER